Arndt Schottelius, a veteran biotech executive, has been appointed chief scientific officer at Affimed NV to lead development of the company’s portfolio of innate cell engager-based medicines for cancer, and to manage its partnerships. Dr Schottelius was most recently head of research and development at Kymab Ltd and before that, chief development officer at MorphoSys AG. Prior to this, he was a medical director for immunology at Genentech. He holds PhD and MD degrees from the Albert Ludwigs University of Freiburg, Germany.
Affimed announced the appointment on 17 March 2020.
Copyright 2020 Evernow Publishing Ltd.